CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 330 enrolled
Drug / intervention
RD-X19 +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05817045
NCT05817045N/ACompleted
CompareCT.gov

A Randomized, Double-Blind, Sham Controlled, Stratified, Pivotal Efficacy and Safety Study of the EmitBio RD-X19 Treatment Device in Individuals 40 Years of Age and Older With Mild COVID-19 in the At-Home Setting

EmitBio Inc.·interventional·Posted Apr 18, 2023·Updated Oct 24, 2024

In Brief

A clinical study evaluating RD-X19 and Sham for COVID-19. Completed, enrolled 330 participants across 48 sites.

Detailed Summary

This is a randomized, double-blind, sham controlled, stratified, pivotal efficacy and safety study of the EmitBio RD-X19 treatment device in Individuals 40 Years of age and older with Mild COVID-19 in the at-home setting.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedApr 18, 2023
Enrollment StartApr 21, 2023
Primary CompletionJun 15, 2024
Study CompletionJun 30, 2024
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 3.2 years ago

Interventions

RD-X19device

Investigational device that uses safe electromagnetic energy to target the oropharynx.

Shamdevice

Investigational device that uses safe electromagnetic energy to target the oropharynx but at energy levels with a lower inactivation potential against SARS-CoV-2 in vitro.